Vaccine shortage: Serum Institute to produce 10 crore doses by August, Bharat Biotech promises 7.8 crore jabs
The sources said the Union Health Ministry and the office of Drugs Controller General of India had sought from both the firms their production plan for June, July, August and September.
Share Via Email
| A+A A- By PTI
NEW DELHI: Amid multiple states reporting a shortage of COVID-19 vaccine, Serum Institute and Bharat Biotech have submitted to the Centre their production plan for the next four months, informing they can ramp it up to 10 crore and 7.8 crore doses respectively by August, official sources said on Wednesday
Haryana to float global tenders to procure COVID-19 vaccines
SECTIONS
Last Updated: May 13, 2021, 11:14 AM IST
Share
Synopsis
States like Uttar Pradesh, Maharashtra, Karnataka, Andhra Pradesh, Telangana, Tamil Nadu and Delhi have already opted for global tenders to meet their needs.
State Health Minister Anil Vij said that this will help the state vaccinate all 18+ citizens of the State at the earliest
Global tenders would be floated by the Haryana government for procurement of COVID-19 vaccines to ensure that all those above 18 in the state are inoculated, Health Minister Anil Vij said on Thursday. During the past few weeks, COVID cases in Haryana have witnessed a surge. The number of total active cases in the state, as on May 12, were 1,07,058.
COVID-19 vaccine: SII, Bharat Biotech to raise production by August
While Pune-based Serum Institute said it can ramp up the production to 10 crore, the Hyderabad-based Bharat Biotech said they can raise the production to 7.8 crore doses till August
BusinessToday.In | May 13, 2021 | Updated 09:33 IST
Serum Institute of India and Bharat Biotech have submitted their production plan for the next four months as several states continue to report the shortages of COVID-19 vaccines.
While Pune-based Serum Institute said it can ramp up the production to 10 crore, the Hyderabad-based Bharat Biotech said they can raise the production to 7.8 crore doses till August.
Whole-time Director of Bharat Biotech Dr V Krishna Mohan told the Union Health Ministry and the office of Drugs Controller General of India (DCGI) that the production of Covaxin can be raised to 3.32 crore in July and 7.82 crore in August, which will also be maintained in September.
Centre, Bharat Biotech willing to invite other companies to scale up Covaxin production ANI | Updated: May 13, 2021 18:22 IST
By Sahil Pandey
New Delhi [India], May 13 (ANI): Amid the reports of coronavirus vaccine shortage from various states, the Central government and Hyderabad-based Bharat Biotech are willing to invite other companies which want to produce COVAXIN in a bid to scale up the vaccine production, said NITI Aayog member, Dr VK Paul, on Thursday.
However, Dr Paul also stressed that COVAXIN can only be produced in the Biosafety level 3 (BSL3) labs. People say that Covaxin should be given to other companies for manufacturing. I am happy to say that Covaxin manufacturing company (Bharat Biotech) has welcomed this when we discussed it with them. Under this vaccine, a live virus is inactivated and this is done only in BSL3 labs. Not every company has this. We give an open invitation to companies who want to do this. Companies tha
Is Covishield better or Covaxin? Everything you should know about coronavirus vaccine
Currently, people in the age group of 18-44 are getting vaccinated with two COVID-19 vaccines approved for use in India, Covaxin, and Covishield.
DNA Web Team
May 13, 2021, 04:50 PM IST
The third phase of the COVID-19 vaccination was kicked off on May 1st in India. After healthcare workers, elderly people, and 45+ people, now people in the age group of 18-44 are getting vaccinated with two COVID-19 vaccines approved for use in India, Covaxin, and Covishield.
1. Vaccination needs to be scaled up and getting vaccinated is important
1/7
Over 8 crore Indian citizens have been successfully vaccinated and lakhs of doses are being exported to other countries as well. While both Covaxin and Covishield have been deemed safe for use, and adverse reactions have been rarely observed, there are also certain possible side effects people need to be aware of. However, getting vaccinated is of utmost priority